Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Treatment-naive and relapsed/refractory MDS patients receiving venetoclax and HMAs have an ORR of 59% with 63% of responders proceeding to transplant. Allogeneic stem cell transplantation after treatment with venetoclax in combination with HMA is associated with prolonged survival.

保存先:
書誌詳細
出版年:Blood Adv
主要な著者: Ball, Brian J., Famulare, Christopher A., Stein, Eytan M., Tallman, Martin S., Derkach, Andriy, Roshal, Mikhail, Gill, Saar I., Manning, Benjamin M., Koprivnikar, Jamie, McCloskey, James, Testi, Rebecca, Prebet, Thomas, Al Ali, Najla H., Padron, Eric, Sallman, David A., Komrokji, Rami S., Goldberg, Aaron D.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2020
主題:
Stimulus Report
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7362378/
https://ncbi.nlm.nih.gov/pubmed/32589727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001482
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料